In a press release, AstraZeneca SpA announced that, contrary to what appeared yesterday in the specialized press, for the second time the Liguria Regional Administrative Court accepted its request to suspend the regional resolution which imposed the replacement of omeprazole and esomeprazole with the drug of the same therapeutic class at a lower price, based on the principle of presumed equivalence. This is an ordinance which reaffirms the principle of protecting citizens' health and the irreplaceability of omeprazole and esomeprazole; in particular, the right to obtain the drug with the greatest therapeutic value in its category, and not the one with the lowest price, is affirmed. With this ordinance, the Regional Administrative Court of the Liguria Region deemed the preliminary investigation carried out by the regional administration regarding the presumed equivalence with the generic drug to be insufficient. It should be noted that the order was issued after the Liguria Regional Administrative Court examined the documentation produced by AIFA. Esomeprazole and omeprazole will therefore resume being fully reimbursable in Liguria, while the question of constitutionality of the regional law will be examined on 31 October.
Source "pharmacist33"
Source "pharmacist33"
